Article Text

PDF
Paper
Evaluation of a human generic formulation of ciclosporin in the treatment of canine atopic dermatitis with in vitro assessment of the functional capacity of phagocytic cells
  1. M. Kovalik, DrVetMed, PhD, MRCVS1,
  2. I. Taszkun, DrVetMed, PhD2,
  3. Z. Pomorski, MVD, PhD2,
  4. M. Kozak, MVD, PhD1,
  5. D. Pomorska, DrVetMed, PhD2,
  6. M. Szczepanik, DrVetMed, PhD2,
  7. P. Wilkolek, DrVetMed, PhD2,
  8. L. Palenik, DrVetMed, PhD, MRCVS1,
  9. D. J. Shaw, BSc, PhD3,
  10. A. H. M. van den Broek, BVSc, PhD, DVR, FRCVS3 and
  11. K. L. Thoday, BVetMed, PhD, DVD, DipECVD, MRCVS3
  1. University of Veterinary Medicine and Pharmacy in Košice, 041 81 Košice, Slovak Republic
  2. Faculty of Veterinary Medicine, University of Life Science in Lublin, 20-612 Lublin, Poland
  3. Veterinary Dermatology Unit, Division of Veterinary Clinical Sciences, Royal (Dick) School of Veterinary Studies and The Roslin Institute, Easter Bush Veterinary Centre, University of Edinburgh, Roslin, Midlothian EH25 9RG
  1. E-mail for correspondence mkovalikos{at}yahoo.com
  • Dr Kovalik is also at Veterinary Dermatology Unit, Division of Veterinary Clinical Sciences, Royal (Dick) School of Veterinary Studies and The Roslin Institute, Easter Bush Veterinary Centre, University of Edinburgh, Roslin, Midlothian EH25 9RG

Statistics from Altmetric.com

IN human beings, ciclosporin A (CsA) was first used to reduce graft rejection but it soon became apparent that it was also effective in the management of severe atopic …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.